Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Amlodipine_thumbnail
Detail Image
Amlodipine_mobile
Book Detail
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

Amlodipine, a widely used calcium channel blocker, shows strong evidence of efficacy and safety in managing high blood pressure and reducing cardiovascular events. Despite the availability of multiple antihypertensive drug classes, blood pressure control remains suboptimal. This review highlights amlodipine’s performance over two decades, backed by large randomized controlled trials. Given its effectiveness in lowering morbidity and mortality, amlodipine should be considered a first-line agent in hypertension treatment.

Published Date